The in vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae were compared with those of erythromycin, levofloxacin, ofloxacin, and minocycline. The MICs of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline for 90%7o of the 43 M. pneumoniae strains tested were 0.063, 0.016, 0.5, 1, and 0.5 ,ug/ml, respectively. In the experimental pulmonary M. pneumoniae infection model in Syrian golden hamsters, sparfloxacin was as eflective as erythromycin when orally administered at 15 mg/kg twice daily for 5 days and more eflective than erythromycin when orally administered at 10 mg/kg once daily for 5 days. Sparfloxacin was more elfective than levofloxacin and ofloxacin in both dosing regimens. The peak concentrations of sparfloxacin in hamster sera after administration of single oral doses of 15 mg/kg were almost the same as those in human sera after administration of single oral doses of 200 mg (the usual clinical dose), and the half-life of sparfloxacin in hamster serum was shorter than that in human serum after administration of a single oral dose of 200 mg. These results suggest that sparfloxacin may be clinically useful for the treatment of M. pneumonwae infections.
Mycoplasma pneumoniae is a major causative organism of pneumonia and accounts for about 20% of total pneumonia infections (6) . The recommended therapeutic drug against M. pneumoniae infections is now erythromycin, which is efficacious in shortening the duration of symptoms (15) . However, an increase in the number of mutants resistant to erythromycin has been reported (11) . So, new chemotherapeutic drugs have been desired for the treatment of mycoplasmal infections. New quinolones (18) with a broad spectrum of activity against gram-positive and gram-negative bacteria have been developed during the past decade, and some of them have been reported to be active against M. pneumoniae (1, 2, 8, 12, 17) . In particular, the in vitro activity of sparfloxacin (10) against M. pneumoniae has been reported to be excellent (8) . In order to estimate the therapeutic potential of sparfloxacin, we compared the anti-M. pneumoniae activities of sparfloxacin with those of other quinolones, erythromycin, and minocycline in vitro and in vivo.
MATERIALS AND METHODS
Compounds. Sparfloxacin and erythromycin were kindly supplied by Dainippon Pharmaceutical Co., Ltd.; ofloxacin and levofloxacin were supplied by Daiichi Pharmaceutical Co., Ltd.; and minocycline was supplied by Nihon Lederle Pharmaceutical Co., Ltd. The new quinolones and minocycline were dissolved in distilled water with or without NaOH, and erythromycin was dissolved in ethanol. All (17) with modified Chanock broth medium (4) consisting of 7 parts PPLO broth without crystal violet (Difco Laboratories, Detroit, Mich.), 2 parts uninactivated horse serum, 1 part 25% fresh yeast extract, 1% glucose, and 0.002% phenol red and adjusted to pH 7.8 and inocula of 105 CFU/ml. The plates, sealed with plate sealers, were then incubated at 37°C in air. In each case, when the color of the medium of the drug-free control changed from red to yellow, the minimal concentration of drug preventing the color change was defined as the MIC (17) .
Assessment of in vivo activities. The in vivo activities of drugs were assessed in a pulmonary M. pneumoniae infection model using Syrian golden hamsters (1, 3, 16) . Each group consisted of five 6-week-old male Syrian golden hamsters weighing about 100 g each (Japan SLC, Shizuoka, Japan). Animals were anesthetized by intraperitoneal injection of ketamine (Sankyo Co., Ltd.) and infected by the intratracheal intubation method described previously (3) Lungs were removed aseptically, and the viable M. pneumoniae cells per lung were counted by the method described previously (14) . Some colonies were used for identification of M. pneumoniae by a growth-inhibition test with anti-M. pneumoniae rabbit serum and by their hemadsorption properties (5) .
For an untreated control, five hamsters similarly received the vehicle 0.2% carboxymethyl cellulose only twice daily for 5 days, and the viable-cell counts in hamster lungs and the estimates of macroscopic severity were performed at 24 h after the final administration. Before treatment (on day 5 after infection), five hamsters were sacrificed and the viable-cell counts in hamster lungs and the estimates of macroscopic severity were also done. In advance of this in vivo estimation, in order to estimate the possibility of the lung lesions being caused by other microorganisms, some homogenized lung lesions were cultured on chocolate agar, BCYE-a agar, and Sabouraud agar but no microorganisms were recovered.
Assessment of macroscopic pulmonary lesions. Lesions in the lungs were limited to the lower right lobe, and the severity of the pulmonary lesions was assessed macroscopically by measuring the extent of the macroscopic pulmonary lesion area according to the criteria shown in Table 1 . This assessment was performed by the investigator who was blinded to the nature of the treatment regimen.
Lung and serum levels of sparfloxacin and ofloxacin. The concentrations of sparfloxacin and ofloxacin in the lungs and sera of male Syrian golden hamsters weighing about 100 g each and given each drug at a single oral dose of 15 mg/kg were determined. Samples were taken 0.5, 1, 2, 4, 6, 12, and 24 h following administration. Three hamsters were sacrificed at each time point to take the lungs and sera. Lungs were weighed and homogenized in 1/15 M phosphate buffer (pH 7.4). After centrifugation, the supernatants were obtained. The sera were appropriately diluted in normal hamster serum. The lung extracts and sera were assayed by the agar well diffusion method with Escherichia coli Kp as a test organism by the method described previously (9) .
Statistical analysis. Differences in the CFUs in lungs and the extent of macroscopic lung lesions between the treated and untreated groups were analyzed by the Mann-Whitney U test for nonparametric analysis. All analyses were conducted with Version II Statview SE software (Abacus Concepts, Inc.).
RESULTS
In vitro activity. The antimycoplasmal activities of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline against 43 strains of M. pneumoniae, including 3 standard strains, is shown in Table 2 .
The ranges of the MICs of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline were 0.031 to 0.063, 0.0039 to 0.031, 0.25 to 0.5, 0.5 to 1, and 0.25 to 1 jig/ml, respectively. The MICs at which 90% of the strains tested were inhibited by sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline were 0.063, 0.016, 0.5, 1, and 0.5 jig/ml, respectively.
The activities of levofloxacin and ofloxacin were less potent than that of erythromycin but similar to that of minocycline, and sparfloxacin showed the highest activity among new quinolones. The MICs of sparfloxacin, erythromycin, levofloxacin, and ofloxacin against the strain M129, which was used for the in vivo test, were 0.063, 0.016, 0.25, and 0.5 ,ug/ml, respectively.
In vivo activity. The in vivo activity of sparfloxacin was compared with those of erythromycin, levofloxacin, and ofloxacin in experimentally induced M. pneumoniae pneumonia in golden hamsters ( Fig. 1 and 2) (Table 3 ). This value was about 1.3-fold higher than that of ofloxacin at the same dose. The half-life of sparfloxacin in lungs was 3.4 h, which was about 4-fold longer than that of ofloxacin.
The mean concentration of sparfloxacin in lungs at 24 h after the administration of a single oral dose of 15 mg/kg was 0.10 ,ug/g, which was higher than the MIC for the M129 strain. The peak concentrations and half-lives of sparfloxacin and ofloxacin in sera after the administration of single oral doses of 15 These results show that the peak concentrations of sparfloxacin and ofloxacin in hamster sera are similar to those of sparfloxacin and ofloxacin in human sera after clinical dosing and that the half-lives of sparfloxacin and ofloxacin in hamster sera are shorter than those of sparfloxacin and ofloxacin in human sera (7, 13 (8, 12, 17) . Sparfloxacin is a new quinolone, which has been reported to show much superior activity against gram-positive bacteria (10) (1) , though they did not make any estimate for sparfloxacin. In the present study, we used doses of 10 and 30 mg/kg/day.
The peak concentrations of sparfloxacin in hamster sera after the administration of single oral doses of 15 mg/kg were almost the same as those in human sera after the administration of single oral doses of 200 mg (the usual clinical dose), and the half-lives of sparfloxacin in hamster sera were shorter than those in human sera (13) . As the maximum concentration of sparfloxacin in lungs was higher than that in hamster serum, it is likely that this is the case in humans. These results suggest that sparfloxacin may be clinically useful for the treatment of M pneumoniae infection. The excellent clinical efficacy of sparfloxacin against respiratory infection, including mycoplasmal pneumonia, has been reported for clinical studies carried out in Japan (19) .
